Candel therapeutics to present preclinical data on therapeutic potential of can-3110 in melanoma at sitc 2024 annual meeting

Needham, mass., oct. 04, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the company will present a poster at the society for immunotherapy of cancer's (sitc) 39th annual meeting taking place november 6-10, 2024 in houston, texas and virtually.
CADL Ratings Summary
CADL Quant Ranking